Demonstration of bile duct patency using radionuclides is often an essential investigation in distinguishing extrahepatic biliary atresia from intrahepatic disease causing severe cholestasis. The improved results from portoenterostomy for biliary atresia, particularly if performed in the first 2 months of life,' together with the deleterious effect of inappropriate laparotomy and biliary surgery for infants with hepatic disease,2 make early accurate diagnosis essential.
Difficulties with the 1311 Rose-Bengal faecal excretion test, which requires a 72 hour stool collection, have prompted consideration of new isotope excretion tests. Iminodiacetic acid (IDA) compounds are rapidly removed from the circulation by the liver and excreted in bile and, when labelled with 99mtechnetium, the biliary-intestinal excretion may conveniently be shown with a gammacamera.
A new IDA compound, diisopropyl IDA (DISIDA) with improved lipid solubility allowing hepatic uptake at a high serum bilirubin concentration and with a shorter hepatobiliary transit time, has theoretical advantages over earlier IDA compounds, which often fail to distinguish biliary atresia from hepatic disease.3 We report an assessment of the value of DISIDA scintigraphy in 50 consecutive infants investigated because of conjugated hyperbilirubinaemia in the first 12 weeks of life.
Patients and methods
All 50 infants were investigated for possible genetic, metabolic, infective, and structural causes of hepatobiliary disease. DISIDA scintigraphy was not carried out in 18 infants as they had either pigmented stools (13), a, antitrypsin deficiency (PiZ) previously diagnosed by phenotyping (four), or the presence of a choledochal cyst on ultrasound (one). DISIDA scintigraphy was performed in 32 infants in whom distinction between biliary atresia and hepatic disease was difficult. Of these, 21 subsequently had 1311 Rose-Bengal faecal excretion studies.
Radionuclide tests. In 32 infants 40 mBq (1 mCi) 99mTc-DISIDA was injected intravenously after a three day course of oral phenobarbitone (5 mg/kg! day). Imaging was carried out at five minute intervals for the first hour and then at hourly intervals for 10 hours or until radioactivity was seen in the intestines. If excretion was still not apparent imaging was repeated at 24 hours. In 21 infants 0-2 mBq (5 RCi)`3 1I Rose-Bengal was injected intravenously. Stools were then collected for three consecutive days, taking care to avoid urinary contamination.
Results
Diagnoses and results of the radionuclide tests are shown in the Table. There was no biliary excretion of DISIDA in 23 infants. Biliary atresia was confirmed at laparotomy in 20 of these. In two infants liver biopsy specimens showed features of bile duct hypoplasia, and their subsequent course confirmed the diagnosis. The other child had histological features of biliary atresia, but laparotomy was not performed because of advanced liver disease with ascites. No post mortem was performed. There was delayed excretion of tracer at 24 hours in three cases: one had a bile duct plug diagnosed at laparotomy, one had a, antitrypsin deficiency, and one had severe familial neonatal hepatitis of unknown aetiology. Excretion of DISIDA was evident by three hours in six infants, one with a, antitrypsin deficiency and five with hepatic disease suggested by liver biopsy and confirmed by subsequent clearing of jaundice. 1311 Rose-Bengal faecal excretion was less than 10% in all 14 with biliary atresia and in four others with acholic stools, one of whom had a, antitrypsin deficiency (delayed excretion of DISIDA) and three with intrahepatic disease (one of whom had no excretion of DISIDA). Diagnostic accuracy was therefore 87% (28 out of 32) for DISIDA and 81% (17 out of 21) for Rose-Bengal. 
